| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 14 | 2023 | 120 | 6.190 |
Why?
|
| Epstein-Barr Virus Infections | 11 | 2024 | 291 | 3.550 |
Why?
|
| HIV Infections | 16 | 2023 | 1888 | 2.380 |
Why?
|
| Burkitt Lymphoma | 9 | 2024 | 146 | 2.310 |
Why?
|
| Herpesvirus 4, Human | 9 | 2024 | 671 | 2.220 |
Why?
|
| Herpesvirus 8, Human | 3 | 2023 | 49 | 1.680 |
Why?
|
| Lymphoma | 4 | 2023 | 322 | 1.590 |
Why?
|
| Malawi | 17 | 2025 | 397 | 1.390 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2024 | 224 | 1.250 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2023 | 162 | 1.250 |
Why?
|
| Histiocytosis, Langerhans-Cell | 4 | 2024 | 223 | 1.240 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 145 | 1.230 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2025 | 15 | 0.970 |
Why?
|
| Child | 41 | 2025 | 24516 | 0.940 |
Why?
|
| Organ Transplantation | 2 | 2024 | 164 | 0.930 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2024 | 139 | 0.830 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.820 |
Why?
|
| Lymphoma, T-Cell | 4 | 2021 | 64 | 0.750 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 1240 | 0.710 |
Why?
|
| Adolescent | 27 | 2025 | 19354 | 0.680 |
Why?
|
| Interleukin-6 | 2 | 2019 | 414 | 0.680 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 297 | 0.660 |
Why?
|
| Anemia | 2 | 2023 | 341 | 0.640 |
Why?
|
| Viral Load | 4 | 2018 | 384 | 0.610 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2020 | 266 | 0.590 |
Why?
|
| Cytokines | 3 | 2021 | 1277 | 0.580 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 142 | 0.570 |
Why?
|
| Humans | 53 | 2025 | 124327 | 0.520 |
Why?
|
| Vincristine | 5 | 2020 | 196 | 0.520 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 1674 | 0.450 |
Why?
|
| Lymphoma, B-Cell | 2 | 2025 | 141 | 0.420 |
Why?
|
| Rituximab | 3 | 2024 | 156 | 0.400 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2025 | 1199 | 0.390 |
Why?
|
| Child, Preschool | 16 | 2025 | 14076 | 0.390 |
Why?
|
| Neoplasms | 4 | 2025 | 2794 | 0.390 |
Why?
|
| Methotrexate | 3 | 2025 | 351 | 0.380 |
Why?
|
| Hydroa Vacciniforme | 1 | 2010 | 3 | 0.360 |
Why?
|
| Male | 27 | 2025 | 60989 | 0.330 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2020 | 136 | 0.330 |
Why?
|
| Disease Management | 2 | 2025 | 519 | 0.320 |
Why?
|
| Young Adult | 12 | 2024 | 8978 | 0.320 |
Why?
|
| Female | 27 | 2025 | 66265 | 0.310 |
Why?
|
| Tanzania | 3 | 2023 | 68 | 0.290 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 501 | 0.280 |
Why?
|
| Prognosis | 6 | 2025 | 4554 | 0.280 |
Why?
|
| Bone Marrow | 3 | 2021 | 325 | 0.270 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1218 | 0.260 |
Why?
|
| Immunotherapy | 4 | 2022 | 661 | 0.260 |
Why?
|
| Prospective Studies | 8 | 2025 | 6084 | 0.260 |
Why?
|
| Retrospective Studies | 9 | 2025 | 16223 | 0.250 |
Why?
|
| Laboratories, Hospital | 1 | 2025 | 21 | 0.240 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 803 | 0.240 |
Why?
|
| Infant | 9 | 2025 | 12476 | 0.240 |
Why?
|
| Doxorubicin | 3 | 2020 | 301 | 0.220 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 872 | 0.220 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2025 | 188 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 172 | 0.210 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2023 | 3 | 0.210 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 421 | 0.210 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 14 | 0.210 |
Why?
|
| Treatment Outcome | 11 | 2025 | 12279 | 0.210 |
Why?
|
| HIV-1 | 2 | 2016 | 463 | 0.200 |
Why?
|
| Adult | 9 | 2024 | 29378 | 0.200 |
Why?
|
| Mucositis | 1 | 2022 | 18 | 0.200 |
Why?
|
| Morbidity | 1 | 2023 | 244 | 0.200 |
Why?
|
| Haploinsufficiency | 1 | 2024 | 257 | 0.200 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 119 | 0.200 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 314 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 353 | 0.200 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 356 | 0.190 |
Why?
|
| Medical Oncology | 1 | 2023 | 215 | 0.190 |
Why?
|
| Perforin | 1 | 2021 | 17 | 0.190 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 324 | 0.180 |
Why?
|
| Virus Replication | 1 | 2023 | 609 | 0.170 |
Why?
|
| Cysticercosis | 1 | 2020 | 21 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 196 | 0.170 |
Why?
|
| Bleomycin | 2 | 2020 | 150 | 0.170 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2020 | 61 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 530 | 0.170 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 29 | 0.170 |
Why?
|
| Anthracyclines | 2 | 2017 | 36 | 0.160 |
Why?
|
| Tertiary Healthcare | 1 | 2019 | 21 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 267 | 0.160 |
Why?
|
| Endemic Diseases | 1 | 2018 | 57 | 0.150 |
Why?
|
| HIV Protease Inhibitors | 1 | 2018 | 53 | 0.150 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 314 | 0.150 |
Why?
|
| Virus Activation | 1 | 2018 | 87 | 0.150 |
Why?
|
| Biopsy | 1 | 2021 | 1237 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2017 | 68 | 0.140 |
Why?
|
| Hodgkin Disease | 2 | 2017 | 293 | 0.140 |
Why?
|
| Asia | 1 | 2017 | 107 | 0.140 |
Why?
|
| Plasma | 1 | 2017 | 96 | 0.130 |
Why?
|
| Europe | 1 | 2017 | 352 | 0.130 |
Why?
|
| HIV | 1 | 2017 | 180 | 0.130 |
Why?
|
| Risk | 1 | 2017 | 749 | 0.120 |
Why?
|
| Developing Countries | 1 | 2017 | 268 | 0.120 |
Why?
|
| Remission Induction | 1 | 2016 | 301 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3425 | 0.120 |
Why?
|
| Angiomatosis, Bacillary | 1 | 2014 | 3 | 0.120 |
Why?
|
| Algorithms | 1 | 2021 | 1612 | 0.110 |
Why?
|
| Risk Factors | 4 | 2023 | 10139 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2018 | 1400 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 1697 | 0.110 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 331 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 166 | 0.100 |
Why?
|
| Child Health Services | 1 | 2013 | 88 | 0.100 |
Why?
|
| Biomarkers | 1 | 2021 | 2977 | 0.100 |
Why?
|
| Adenoviridae Infections | 1 | 2011 | 70 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1127 | 0.090 |
Why?
|
| Proteomics | 1 | 2014 | 489 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 225 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 3133 | 0.090 |
Why?
|
| Recurrence | 2 | 2024 | 1423 | 0.090 |
Why?
|
| Survival Rate | 4 | 2017 | 2020 | 0.080 |
Why?
|
| United States | 2 | 2023 | 10767 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2025 | 8184 | 0.080 |
Why?
|
| DNA, Viral | 3 | 2017 | 479 | 0.080 |
Why?
|
| Genomics | 1 | 2017 | 1486 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1085 | 0.080 |
Why?
|
| Transcriptome | 1 | 2014 | 936 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1887 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 5807 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 3342 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2303 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5106 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 810 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2018 | 230 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1929 | 0.070 |
Why?
|
| Prednisone | 2 | 2019 | 274 | 0.070 |
Why?
|
| Time Factors | 1 | 2016 | 6262 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2017 | 4532 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 860 | 0.060 |
Why?
|
| Lymph Nodes | 2 | 2019 | 376 | 0.060 |
Why?
|
| Adenine Nucleotides | 1 | 2024 | 41 | 0.060 |
Why?
|
| Arabinonucleosides | 1 | 2024 | 32 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 78 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2025 | 168 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 100 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2024 | 209 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1460 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2024 | 226 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2024 | 194 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 298 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 121 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2022 | 238 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 382 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2022 | 323 | 0.040 |
Why?
|
| Chromatin | 1 | 2024 | 554 | 0.040 |
Why?
|
| Anticestodal Agents | 1 | 2020 | 3 | 0.040 |
Why?
|
| Praziquantel | 1 | 2020 | 11 | 0.040 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 15 | 0.040 |
Why?
|
| Taenia solium | 1 | 2020 | 11 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 172 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 191 | 0.040 |
Why?
|
| Albendazole | 1 | 2020 | 29 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 124 | 0.040 |
Why?
|
| Middle Aged | 4 | 2024 | 26442 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 235 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 295 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 775 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 140 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 1272 | 0.040 |
Why?
|
| Proto-Oncogenes | 1 | 2017 | 37 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1154 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 127 | 0.030 |
Why?
|
| Viremia | 1 | 2016 | 128 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 449 | 0.030 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2014 | 3 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1004 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2016 | 3371 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 37 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 63 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2024 | 2607 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 197 | 0.030 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 176 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1320 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 237 | 0.030 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.030 |
Why?
|
| Botswana | 1 | 2013 | 76 | 0.030 |
Why?
|
| Child Nutrition Disorders | 1 | 2013 | 76 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1333 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 1569 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 83 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 605 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1267 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 1761 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 767 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 226 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3086 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 34134 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 133 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 481 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1694 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 662 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 229 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2805 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1017 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 539 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1015 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 764 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 525 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 802 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7167 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1245 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 543 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 1584 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 17723 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 1182 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1684 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 19460 | 0.020 |
Why?
|